Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
Purpose: To determine the incidence of COVID 19 in a series of registered patients with non-muscle invasive bladder cancer, treated by TUR-BT and intravesical BCG. Patients and method: We analysed 127 patients with nonmuscle invasive bladder cancer, in the medium/high risk group, registered between...
Saved in:
| Main Authors: | Gabriel GLUCK, B. RADU, Angelica IONESCU, A. BOAR, Ioanel SINESCU |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bucharest College of Physicians
2020-06-01
|
| Series: | Modern Medicine |
| Subjects: | |
| Online Access: | https://medicinamoderna.ro/wp-content/uploads/2020/06/RMM_art-7.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients
by: Zhen Li, et al.
Published: (2025-02-01) -
Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders
by: Toni Boban, et al.
Published: (2025-03-01) -
Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
by: Amandeep Arora, et al.
Published: (2025-06-01) -
Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models
by: Lauren Daniel, et al.
Published: (2025-09-01) -
Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
by: Aykut Başer
Published: (2020-12-01)